Skip to content
10-Q

Quarterly Report

Biohaven Pharmaceutical Holding Company Ltd.

0001689813-22-000041

← back to feed
Filed
May 10, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 6, 2022 71.04M sh
Shares Diluted Q1 2022 · Mar 31, 2022 70.33M sh
Shares Diluted Q1 2022 · Mar 31, 2021 62.04M sh
Capex Q1 2022 · Mar 31, 2022 $512K
Capex Q1 2022 · Mar 31, 2021 $1.19M
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$23.64M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$205.67M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $169.07M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $171.95M
Stockholders Equity Q1 2022 · Mar 31, 2022 −$462.29M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$739.38M
Current Liabilities Q1 2022 · Mar 31, 2022 $576.11M
Current Liabilities Q1 2022 · Dec 31, 2021 $534.2M
Total Liabilities Q1 2022 · Mar 31, 2022 $1.84B
Total Liabilities Q1 2022 · Dec 31, 2021 $1.76B
Current Assets Q1 2022 · Mar 31, 2022 $1.17B
Current Assets Q1 2022 · Dec 31, 2021 $876.25M
Total Assets Q1 2022 · Mar 31, 2022 $1.37B
Total Assets Q1 2022 · Dec 31, 2021 $1.08B
Eps Diluted Q1 2022 · Mar 31, 2022 −$2.97
Eps Diluted Q1 2022 · Mar 31, 2021 −$4.27
Eps Basic Q1 2022 · Mar 31, 2022 −$2.97
Eps Basic Q1 2022 · Mar 31, 2021 −$4.27
Sga Expense Q1 2022 · Mar 31, 2022 $227.24M
Sga Expense Q1 2022 · Mar 31, 2021 $159.52M
Rd Expense Q1 2022 · Mar 31, 2022 $119.1M
Rd Expense Q1 2022 · Mar 31, 2021 $107.11M
Operating Income Q1 2022 · Mar 31, 2022 −$53.83M
Operating Income Q1 2022 · Mar 31, 2021 −$235.67M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $26.34M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $12.86M
Revenue Q1 2022 · Mar 31, 2022 $318.85M
Revenue Q1 2022 · Mar 31, 2021 $43.82M